Emerald Advisers LLC Grows Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Advisers LLC grew its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 11.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,623,449 shares of the medical technology company's stock after buying an additional 167,416 shares during the period. Emerald Advisers LLC owned approximately 1.11% of Alphatec worth $16,462,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after acquiring an additional 2,306 shares during the period. Comerica Bank grew its stake in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after acquiring an additional 1,248 shares during the period. Quarry LP grew its stake in shares of Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Alphatec in the fourth quarter worth approximately $76,000. Finally, AlphaQuest LLC bought a new stake in shares of Alphatec in the fourth quarter worth approximately $80,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ATEC. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 target price for the company in a research report on Monday, June 16th. Finally, Needham & Company LLC restated a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Stock Performance

Shares of ATEC traded up $0.03 during mid-day trading on Monday, reaching $11.02. The stock had a trading volume of 159,908 shares, compared to its average volume of 2,069,975. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -9.60 and a beta of 1.05. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $13.14. The business has a fifty day moving average of $11.87 and a 200 day moving average of $11.04.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The business's revenue for the quarter was up 22.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.34) earnings per share. On average, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alphatec news, EVP Craig E. Hunsaker sold 186,122 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total value of $2,296,745.48. Following the completion of the transaction, the executive vice president directly owned 1,463,896 shares in the company, valued at $18,064,476.64. This represents a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Karen K. Mcginnis sold 3,963 shares of the business's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $12.11, for a total transaction of $47,991.93. Following the completion of the transaction, the director directly owned 68,709 shares in the company, valued at $832,065.99. This trade represents a 5.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 294,065 shares of company stock worth $3,633,172 over the last three months. 20.90% of the stock is currently owned by company insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.